• Tasly: ​​Net profit attributable to parent company in the first quarter was 295 million yuan, a year-on-year increase of 11.58%

    In the context of national policies that are favorable to traditional Chinese medicine, Tasly, a leading modern traditional Chinese medicine company, has seized development opportunities and has a good start in 2024. On the evening of April 25, the 2024 first quarter report released by Tasly (600535) showed that during the reporting period, the company achieved operating income of 2.049 billion yuan; net profit attributable to the parent company was 295 million yuan, a year-on-year increase of 11.58%, and the operating quality remained good. Tasly, which has firmly established its leading position in the research and development of traditional Chinese medicines, currently has as many as 9 innovative traditional Chinese medicines in Phase III clinical trials, which indicates that the company will gradually launch new products on the market in the next few years and continue to expand the company\’s business growth space.

    US stock news April 25, 2024